New Haven drug developer Rib-X Pharmaceuticals Inc. announced Wednesday a pair of executive promotions.
Erin Duffy was named chief scientific officer and Jarrod Longcor was elevated to vice president of corporate development.
The bedrock of Rib-X’s antibiotic treatment is its proprietary formulation that blocks the ability of bacteria to manufacture a key protein necessary for survival.
Duffy and Longcor are both credited for involvement with the Rib-X team that developed an antibiotics targeting regime in which drug giant Sanofi recently signed on a co-partner to commercialize it.
Duffy joined Rib-X early in 2002 and previously served as vice president of discovery research. She has more than 20 years of research experience in chemistry, biology and related disciplines.
Before joining Rib-X, she was across town at Achillion Pharmaceuticals Inc. and, before that, spent five years as a computational chemist with Pfizer Global Research and Development in Groton.
Duffy trained at Yale University, received her doctorate in physical-organic chemistry and moved to the molecular biophysics and biochemistry department for postdoctoral work.
Longcor joined Rib-X in 2007 and previously served as senior director, business development. He has over 15 years of experience in the biopharmaceutical industry, combining research skill with 10 years of experience in business development.
Prior to joining Rib-X, Longcor served as the director of business development at MaxCyte Inc., where he was responsible for developing regional partnerships.
Longcor received his MBA from St. Joseph’s Haub School of Business, a Masters of Medicine from Boston University School of Medicine and his B.S. from Dickinson College.
